All In Biotech

Drug Trial Radar · NCT01422304

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

A Randomized, Controlled, Parallel-group, Double-blind Trial of Sugammadex or Usual Care (Neostigmine or Spontaneous Recovery) for Reversal of Rocuronium- or Vecuronium-induced Neuromuscular Blockade in Patients Receiving Thromboprophylaxis and Undergoing Hip Fracture Surgery or Joint (Hip/Knee) Replacement (Protocol No. P07038)

Last checked: Nov 19, 2026Latest source record: Feb 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,198

Actual

Start

Oct 12, 2011

Primary completion

Sep 26, 2012

Study completion Sep 26, 2012

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the effect of reversal of neuromuscular blockade with sugammadex compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of post-surgical bleeding events and on coagulation parameters in participants undergoing hip fracture surgery or joint (hip/knee) replacement surgery with neuromuscular blockage induced by rocuronium or vecuronium.

Conditions

  • Neuromuscular Blockade
  • Arthroplasty, Replacement, Hip
  • Arthroplasty, Replacement, Knee
  • Blood Coagulation
  • Antithrombotic Agents

Interventions

  • SugammadexDrug

    Sugammadex 4 mg/kg intravenously

  • neostigmine and glycopyrrolate or atropineDrug

    Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels

  • Placebo to neostigmineDrug

    Normal saline (NaCl 0.9%)

  • Placebo to sugammadexDrug

    Normal saline (NaCl 0.9%)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug AdministrationTime frame: Up to 24 hours post study drug administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.